中国经济网北京12月1日讯太龙药业（600222）(600222.SH)今晚发布关于控股股东筹划重大事项停牌的 公告。公司于2025年12月1日收到控股股东泰容产投的通知，泰容产投正在筹划股份转让事宜，该事项 可能导致公司控制权变更。 鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动， 根据《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第4号--停复牌》等有 关规定，经公司向上海证券交易所申请，公司股票(证券简称：太龙药业，证券代码：600222)自2025年 12月2日(星期二)开市起停牌，预计停牌时间不超过2个交易日。 ...

Group 1 - The controlling shareholder of Tailong Pharmaceutical is planning to transfer shares, which may lead to a change in company control. The company's stock will be suspended from trading starting December 2 [1][3][6] - The suspension of trading is expected to last no more than two trading days, during which the company will comply with information disclosure obligations as per legal regulations [3][6] - As of the end of the third quarter, the controlling shareholder, Zhengzhou TaiRong Industrial Investment Co., holds 82,441,168 shares, accounting for 14.37% of the total shares [8][9] Group 2 - For the first three quarters of the year, Tailong Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [11][12] - The company's main business includes drug manufacturing and research services, covering four segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [8]

Core Viewpoint - Tai Long Pharmaceutical (600222) announced that its controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd. ("Tai Rong Investment"), is planning a share transfer that may lead to a change in company control [2] Group 1: Shareholder and Control Changes - Tai Rong Investment holds 82.44 million shares, accounting for 14.37% of the total share capital, with a corresponding market value of approximately 707 million yuan [2] - The company will suspend trading from December 2, 2025, for no more than two trading days to avoid abnormal stock price fluctuations [2] - Tai Rong Investment acquired control of Tai Long Pharmaceutical in January 2022 at a price of 9.7 yuan per share, totaling around 800 million yuan [2] Group 2: Business Operations and Financial Performance - Tai Long Pharmaceutical focuses on drug manufacturing and research services, including four main business segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [3] - The company reported a net profit of 43.56 million yuan for 2023 and 50.53 million yuan for 2024, with a revenue of 1.187 billion yuan in the first three quarters of the current year, reflecting a year-on-year decline of 11.47% [3][4] - The decline in revenue is attributed to the ongoing standardization work for major products in the national collection of traditional Chinese medicine, which has not yet fully materialized [4] Group 3: Investor Returns - Tai Long Pharmaceutical plans to distribute cash dividends of 0.14 yuan per 10 shares to all shareholders before the third quarter of 2025, amounting to approximately 7.74 million yuan (including tax), which represents 30.57% of the company's net profit attributable to shareholders for the same period [4][5]

Core Viewpoint - TaiLong Pharmaceutical (600222) announced a suspension of trading due to potential changes in company control as its major shareholder, Zhengzhou TaiRong Industrial Investment Co., Ltd., is planning to transfer shares [2][4]. Group 1: Company Announcement - The trading suspension for TaiLong Pharmaceutical will begin on December 2, 2025, and is expected to last no more than two trading days [4]. - The company operates in the pharmaceutical manufacturing and research services sector, which includes four main business segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [4]. Group 2: Stock Performance - TaiLong Pharmaceutical's stock has shown strong performance this year, with a cumulative increase of nearly 70%, and a significant rise of approximately 25% in November alone [4]. - On December 1, 2025, the stock reached a peak increase of 6.72%, bringing the total market capitalization to 4.9 billion [4]. Group 3: Financial Performance - For the first three quarters of the year, the company reported revenue of 1.187 billion, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million, down 12.36% [6]. - In the third quarter, the company achieved revenue of 424 million, a year-on-year increase of 2.67%, and a net profit of 5.98 million, reflecting a significant year-on-year growth of 162.48% [6]. - The adjusted net profit after excluding non-recurring items for the first three quarters was 20.73 million, showing a year-on-year increase of 6.38% [6].

太龙药业（600222）明起停牌。 12月1日晚间，太龙药业（600222）发布公告称，公司控股股东郑州泰容产业投资有限公司正在筹划公司股份转让事宜，该事项可能导致公司控制权 发生变更。 | 证券代码 | 证券简称 | 信分期 @ 地 | 停牌起始日 | 은 딸 | 停留级 上 | I | 夏牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | | 600222 | 太龙药业 | A B2 信 運 | 2025/12/2 | | | | | 鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司股价异常波动，根据有关规定，经公司向上海证券交易所申 请，公司股票（证券简称：太龙药业，证券代码：600222）自2025年12月2日（星期二）开市起停牌，预计停牌时间不超过2个交易日。 公开资料显示，太龙药业主要业务为药品制造和药品研发服务，具体包含药品制剂、中药饮片、药品研发服务和药品药材流通四个业务板块。 业绩方面，公司三季报显示，今年前三季度，公司实现营业收入11.87亿元，同比减少11.47 ...

Group 1: BYD Performance - BYD announced a production of 474,200 new energy vehicles (NEVs) and sales of 480,200 NEVs in November 2025 [1] - Cumulative production for the year reached 4,117,600 units, representing a year-on-year increase of 7.29% [1] - Cumulative sales for the year totaled 4,182,000 units, with a year-on-year growth of 11.30% [1] - In November, BYD exported 131,900 NEVs and installed approximately 27.669 GWh of power batteries and energy storage batteries [1] Group 2: Investment Initiatives - Lushin Venture Capital plans to establish a 400 million yuan investment fund focusing on life sciences, advanced manufacturing, and AI [2] - Chint Electric's wholly-owned subsidiary intends to invest up to 201 million yuan in a green private equity investment fund with a total scale of 700 million yuan [8] Group 3: Corporate Actions - Qianwei Central Kitchen will conduct a shareholder reward activity, offering a product package worth 200 yuan to individual shareholders holding 100 shares or more [3] - Huaxia Happiness plans to use trust beneficiary rights to offset financial debts totaling up to 24 billion yuan as part of its debt restructuring plan [4] - Tailong Pharmaceutical's controlling shareholder is planning a share transfer, leading to a temporary suspension of the company's stock [5] - ST Xianhe has applied to revoke other risk warnings, pending approval from the Shenzhen Stock Exchange [6] - *ST Yuancheng's stock will be delisted due to a market value below 500 million yuan for 20 consecutive trading days [7] Group 4: Sales and Contracts - SAIC Group reported sales of 4,108,000 vehicles from January to November 2025, a year-on-year increase of 16.4% [10] - Geely Automobile's total sales in November reached 310,428 units, marking a 24% increase year-on-year [11] - Far East Holdings' subsidiaries secured contracts worth 2.383 billion yuan in November, positively impacting future earnings [18] - Samsung Medical's subsidiary signed a contract for an annual bidding project in Indonesia worth approximately 160 million yuan [19] - Zhongchao Holdings' subsidiaries recently won contracts totaling 1.318 billion yuan [20] - Changhua Group received a project development notice from a domestic automaker, with an expected total sales amount of approximately 732 million yuan [21]

Group 1 - The core point of the news is that Tai Long Pharmaceutical's controlling shareholder is planning to transfer shares, which may lead to a change in company control, resulting in the suspension of the company's stock from December 2 [1][2][5] - The stock suspension is expected to last no more than two trading days, and the company will comply with legal disclosure obligations during this period [2][5] - As of the end of the third quarter, the controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., holds 82,441,168 shares, accounting for 14.37% of the total shares [6][7] Group 2 - For the first three quarters of the year, Tai Long Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [9][10] - The company's main business includes pharmaceutical manufacturing and research services, divided into four segments: pharmaceutical formulations, traditional Chinese medicine pieces, pharmaceutical research services, and pharmaceutical materials circulation [6]

Core Viewpoint - TaLong Pharmaceutical's controlling shareholder is planning to transfer company shares, which may lead to a change in control. The company's stock has been suspended from trading since December 2, 2025, for a period not exceeding two trading days [2][4]. Group 1: Shareholder Information - The controlling shareholder, Zhengzhou TaiRong Industrial Investment Co., Ltd. (TaiRong Investment), holds 82,441,168 shares, accounting for 14.37% of the total shares [9][10]. - The actual controller of TaLong Pharmaceutical is the Zhengzhou High-tech Industrial Development Zone Management Committee, which holds 98.17% of Zhengzhou High-tech Investment Holding Group Co., Ltd. [10]. Group 2: Business Overview - TaLong Pharmaceutical's main business includes drug manufacturing and research services, covering four segments: drug formulation, traditional Chinese medicine pieces, drug research services, and drug material circulation [9]. Group 3: Financial Performance - For the first three quarters, TaLong Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%. The net profit attributable to shareholders was 25.33 million yuan, down 12.36% year-on-year [12]. - The company's total revenue for the latest quarter was 1.187 billion yuan, with total costs of 1.167 billion yuan, resulting in an operating profit of 3.5 million yuan [13].

北京商报讯（记者丁宁）12月1日晚间，太龙药业（600222）发布公告称，公司控股股东郑州泰容产业 投资有限公司正在筹划公司股份转让事宜，该事项可能导致公司控制权发生变更。 太龙药业表示，鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，避免造成公司 股价异常波动，根据有关规定，经公司向上交所申请，公司股票自12月2日开市起停牌，预计停牌时间 不超过2个交易日。 （文章来源：北京商报） ...

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) announced that it received a notification from its controlling shareholder, Tai Rong Chan Investment, regarding a planned share transfer that may lead to a change in the company's control [1] Group 1 - The share transfer is being planned by the controlling shareholder, which indicates potential significant changes in the company's governance structure [1] - The company's stock will be suspended from trading starting December 2, 2025, with an expected suspension period of no more than 2 trading days [1]